These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1395 related articles for article (PubMed ID: 33712445)

  • 1. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
    Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.
    Akhand SS; Liu Z; Purdy SC; Abdullah A; Lin H; Cresswell GM; Ratliff TL; Wendt M
    Cancer Immunol Res; 2020 Dec; 8(12):1542-1553. PubMed ID: 33093218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of anti-miRNA21 sensitizes PD-L1
    Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH
    Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-cell-secreted CXCL11 promoted CD8
    Gao Q; Wang S; Chen X; Cheng S; Zhang Z; Li F; Huang L; Yang Y; Zhou B; Yue D; Wang D; Cao L; Maimela NR; Zhang B; Yu J; Wang L; Zhang Y
    J Immunother Cancer; 2019 Feb; 7(1):42. PubMed ID: 30744691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
    Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
    Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
    Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
    Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
    Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer.
    Pingili AK; Chaib M; Sipe LM; Miller EJ; Teng B; Sharma R; Yarbro JR; Asemota S; Al Abdallah Q; Mims TS; Marion TN; Daria D; Sekhri R; Hamilton AM; Troester MA; Jo H; Choi HY; Hayes DN; Cook KL; Narayanan R; Pierre JF; Makowski L
    Cell Rep; 2021 Jun; 35(12):109285. PubMed ID: 34161764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade.
    Luo L; Jiang M; Wu H; Liu Y; Wang H; Zhou C; Ren S; Chen X; Jiang T; Xu C
    Cancer Immunol Immunother; 2024 Jun; 73(8):147. PubMed ID: 38833156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
    Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y
    Int Immunopharmacol; 2024 Aug; 137():112478. PubMed ID: 38901243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance.
    Ayoub M; Shinde-Jadhav S; Mansure JJ; Alvarez F; Connell T; Seuntjens J; Piccirillo CA; Kassouf W
    Sci Rep; 2019 Apr; 9(1):6348. PubMed ID: 31015520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
    Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.